Editas Medicine financials
$2.59+3.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M |
| Gross profit | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M | -$134.8M | -$140.9M | -$113.7M | -$119.9M | -$97.2M |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M | -$116.0M | -$133.7M | -$110.0M | -$120.3M | -$97.2M |
| Net margin | −395.0% | −733.7% | −196.1% | −1118.3% | −753.6% | −127.8% | −651.4% | −344.3% | −876.5% | −1606.3% |
| Diluted EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | $-2.33 | $-2.98 | $-3.02 |
| EBITDA | -$94.1M | -$233.1M | -$163.1M | -$219.6M | -$188.1M | -$130.9M | -$138.1M | -$110.5M | -$117.3M | -$96.0M |
| Operating cash flow | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M | -$179.8M | -$40.7M | -$45.7M | -$9.4M | -$50.2M |
| Free cash flow | -$165.8M | -$219.1M | -$136.9M | -$181.5M | -$171.8M | -$187.0M | -$46.8M | -$50.5M | -$11.5M | -$53.7M |
| Diluted shares | 88.7M | 82.3M | 76.0M | 68.7M | 67.6M | 58.6M | 50.0M | 47.1M | 40.3M | 32.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $146.6M | $131.5M | $123.7M | $141.5M | $203.5M | $139.7M |
| Short-term investments | $0.00 | $138.4M | $199.5M | $202.8M | $296.3M | $262.4M |
| Total debt | $58.6M | $57.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M | $572.6M |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M | $179.0M |
| Shareholders' equity | $27.3M | $134.3M | $349.1M | $360.7M | $553.6M | $393.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology